EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke

C. L. A. Bassetti\textsuperscript{a,b,*}, W. Randerath\textsuperscript{c,*}, L. Vignatelli\textsuperscript{d}, L. Ferini-Strambi\textsuperscript{e}, A.-K. Bril\textsuperscript{f}, M. R. Bonsignore\textsuperscript{g}, L. Grote\textsuperscript{h}, P. Jennnum\textsuperscript{i}, D. Leys\textsuperscript{j}, J. Minnerup\textsuperscript{k}, L. Nobili\textsuperscript{l}, T. Tonia\textsuperscript{m}, R. Morgan\textsuperscript{n}, J. Kerry\textsuperscript{o}, R. Riha\textsuperscript{p,q}, W. T. McNicholas\textsuperscript{r,s,t,†} and V. Papavasileiou\textsuperscript{u,v,†}

\textsuperscript{*}Neurology Department, Medical Faculty, University Hospital, Bern, Switzerland; \textsuperscript{b}Department of Neurology, Sechenov First Moscow State Medical University, Moscow, Russia; \textsuperscript{c}Clinic of Pneumology and Allergology, Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Institute of Pneumology at the University of Cologne, Sollingen, Germany; \textsuperscript{d}Servizio di Epidemiologia e Biostatistica IRCCS, Istituto delle Scienze Neurologiche di Bologna Ospedale Bellaria, Bologna; \textsuperscript{e}Department of Neurology OSR-Turro, Sleep Disorder Center, Vita-Salute San Raffaele University, Milan, Italy; \textsuperscript{f}Department of Pulmonary Medicine, University and University Hospital Bern, Bern, Switzerland; \textsuperscript{g}PROMISE Department, Division of Respiratory Medicine, DiBiMIS, University of Palermo and IBIM-CNR, Palermo, Italy; \textsuperscript{h}Sleep Disorders Center, Department of Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg, Sweden; \textsuperscript{i}Danish Center for Sleep Medicine, Rigshospitalet, Copenhagen, Denmark; \textsuperscript{j}Department of Neurology, University of Lille, Lille, France; \textsuperscript{k}Department of Neurology and Institute for Translational Neurology, University of Muenster, Muenster, Germany; \textsuperscript{l}Child Neuropsychiatry Unit, Gasiini Institute DINOGMI, University of Genova, Genoa, Italy; \textsuperscript{m}Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; \textsuperscript{n}Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; \textsuperscript{o}Library and Information Service, Leeds Teaching Hospitals NHS Trust, Leeds; \textsuperscript{p}Sleep Research Unit, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; \textsuperscript{q}Department of Sleep Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK; \textsuperscript{r}Department of Respiratory and Sleep Medicine, St Vincent’s University Hospital, Dublin; \textsuperscript{s}School of Medicine, University College Dublin, Dublin, Ireland; \textsuperscript{t}First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; \textsuperscript{u}Leeds Teaching Hospital NHS Trust, Leeds; and \textsuperscript{v}Medical School, University of Leeds, Leeds, UK

Keywords: insomnia, outcome, PLMS, restless legs, risk, sleep disorders, breathing, sleep disorders, stroke

Background: Sleep disorders are highly prevalent in the general population and may be linked in a bidirectional fashion to stroke, which is one of the leading causes of morbidity and mortality.

Aim: Four major scientific societies established a task force of experts in neurology, stroke, respiratory medicine, sleep medicine and methodology to critically evaluate the evidence regarding potential links and the impact of therapy.

Materials and methods: Thirteen research questions were evaluated in a systematic literature search using a stepwise hierarchical approach: first, systematic reviews/meta-analyses; second, primary studies post-dating the systematic reviews/meta-analyses. A total of 445 studies were evaluated and 88 were included. Statements were generated regarding current evidence and clinical practice.

Results: Severe obstructive sleep apnoea (OSA) doubles the risk for incident stroke, especially in young to middle-aged patients. Continuous positive airway pressure (CPAP) may reduce stroke risk, especially in treatment-compliant patients. The prevalence of OSA is high in stroke patients and can be assessed by polygraphy. Severe OSA is a risk factor for recurrence of stroke and may be associated with stroke mortality, whilst CPAP may improve stroke outcome. It is not clear if insomnia increases stroke risk, whilst the pharmacotherapy of insomnia may increase it. Periodic limb movements in

Correspondence: W. Randerath, Bethanien Hospital, University of Cologne, Pneumology, Auferhofer Str. 169, Sollingen 42699, Germany (tel.: +49 212 63 6000; fax: +49 212 63 6005; e-mail: randerath@klinik-bethanien.de) and C. L. A. Bassetti, Neurology Department, Inselspital, University of Bern, Freiburgstrasse 18, 3010 Bern, Switzerland (tel.: +41 31 632 30 66; fax: +41 31 632 96 79; e-mail: Claudio.Bassetti@insel.ch).

*Co-shared first authorship
†Co-shared senior authorship

Evidence suggests a bidirectional relationship between sleep and stroke. However, the pathophysiological base of the associations and the possibilities of improving prevention and outcome through sleep-related interventions require further evaluation. http://bit.ly/36De7Cy

This article is co-published by the European Journal of Neurology and the European Respiratory Journal.

This manuscript was handled by Prof. Schapira then by Prof. Sommer, and D. Leys was not a part of the editorial process.

\textsuperscript{a}Correspondence: W. Randerath, Bethanien Hospital, University of Cologne, Pneumology, Auferhofer Str. 169, Sollingen 42699, Germany (tel.: +49 212 63 6000; fax: +49 212 63 6005; e-mail: randerath@klinik-bethanien.de) and C. L. A. Bassetti, Neurology Department, Inselspital, University of Bern, Freiburgstrasse 18, 3010 Bern, Switzerland (tel.: +41 31 632 30 66; fax: +41 31 632 96 79; e-mail: Claudio.Bassetti@insel.ch).

*Co-shared first authorship
†Co-shared senior authorship

Evidence suggests a bidirectional relationship between sleep and stroke. However, the pathophysiological base of the associations and the possibilities of improving prevention and outcome through sleep-related interventions require further evaluation. http://bit.ly/36De7Cy

This article is co-published by the European Journal of Neurology and the European Respiratory Journal.

This manuscript was handled by Prof. Schapira then by Prof. Sommer, and D. Leys was not a part of the editorial process.
sleep (PLMS), but not restless limb syndrome (RLS), may be associated with an increased risk of stroke. Preliminary data suggest a high frequency of post-stroke insomnia and RLS and their association with a less favourable stroke outcome, whilst treatment data are scarce.

**Discussion/Conclusion:** Overall, the evidence base is best for OSA relationship with stroke and supports active diagnosis and therapy. Research gaps remain especially regarding insomnia and RLS/PLMS relationships with stroke.

---

**Introduction**

Stoke is defined as an acute and focal neurological brain damage due to ischaemia or haemorrhage. It represents the second most common cause of death and the third most common cause of disability-adjusted life-years worldwide [1]. The burden of stroke is greater in younger people and the incidence of stroke is increasing in this group [1]. Stroke is a heterogeneous condition with a variety of underlying mechanisms and causes. The risk of stroke is affected by non-modifiable (e.g. age, family history) and potentially modifiable factors (e.g. hypertension, current smoking, alcohol consumption, obesity, diabetes, lack of physical activity, psychosocial stress and depression) [2].

Sleep-wake disorders (SWDs) are very frequent in the general population and have a major impact on performance, quality of life as well as overall health status. The most common SWDs are sleep-disordered breathing (SDB), insomnia and sleep-related movement disorders, such as restless limb syndrome (RLS) and periodic limb movements in sleep (PLMS) [3].

Sleep-disordered breathing is highly prevalent and may present as obstructive or central apnoeas and hypopnoeas, and/or hypoventilation. The obstructive form is most common and recent population-based epidemiological studies have reported a prevalence of obstructive apnoeas and hypopnoeas per hour of sleep (AHI) ≥15 in up to 25% of women and 50% of men. The prevalence increases with age [4,5]. Benjafeld et al. [6] recently described a global prevalence of 425 million (399–450 million) adults aged 30–69 years having an AHI ≥15 events per hour.

The association of obstructive SDB and clinical symptoms, defined as obstructive sleep apnoea syndrome (OSA), is less prevalent, affecting about 10% of the male and 5% of the female population [4,7]. Associations are reported between OSA and a wide range of behavioural and clinical disorders that include fatigue, excessive daytime sleepiness, insomnia and non-restorative sleep, attention and cognitive deficits, and increased frequency of accidents, in addition to cardiovascular disorders, hypertension, diabetes mellitus and the metabolic syndrome, and depression [4,8,9]. Cluster analysis of large databases has demonstrated different clinical phenotypes of OSA according to symptoms (sleepiness, insomnia, depression), anthropometric factors (age, gender, body constitution) and comorbidities [10–12].

Insomnia is defined by complaints of difficulties initiating sleep, maintaining sleep or waking up too early and their association with diurnal symptoms such as fatigue, sleepiness, attention/concentration problems, impaired social or occupational performance, and mood disturbance [13]. In this context, it is important to stress the fact that (i) the current definition of insomnia does not require an objective shortening of sleep duration and that (ii) short sleepers without diurnal complaints are not classified as insomniacs. Insomnia affects over 20% of the general population and up to 5%–10% use hypnotics [13], with a tendency in recent years to an increase in some countries including the USA and an increase in benzodiazepine-related deaths [14]. Associations have been reported between insomnia and depression, anxiety, hypertension, diabetes and cardiovascular disorders [15–19].

Restless limb syndrome is defined by the presence of an urge to move the limbs (usually the legs), accompanied by unpleasant sensations, which worsen during rest, in the evening or at night and are relieved by movement [20,21]. A positive family history and response to dopaminergic drugs, as well as the presence of periodic limb movements during wakefulness or sleep, support the diagnosis of RLS [21]. The frequency of RLS in the general population is as high as 5%–15%; 2%–5% present with frequent or severe symptoms [22]. An association has been reported between RLS and insomnia, excessive daytime sleepiness, iron deficiency/anaemia, uraemia, hypertension, diabetes, depression, pain, neurological disorders, chronic obstructive pulmonary disease and cardiovascular disorders [23–25].

Other SWDs such as extremes of sleep duration (short and long sleep) as well as circadian rhythm disorders (e.g. related to shift work) have been linked to cardiovascular diseases, such as stroke, and have been suggested to negatively influence their course and outcome [26–35].
Accordingly, the American Heart Association suggested diagnosis and treatment strategies for SWDs in the management of stroke [36]. However, the extent and relevance of this bidirectional relationship between sleep and stroke remain a matter of debate.

In order to assess the current knowledge about the link between sleep disorders and stroke, and motivated by previous successful multidisciplinary activities [3,9], the European Academy of Neurology (EAN), the European Respiratory Society (ERS), the European Sleep Research Society (ESRS) and the European Stroke Organization (ESO) created a task force to produce a common statement on this topic.

**Methods**

The multidisciplinary task force was composed of 15 experts in neurology, pneumology, sleep medicine, stroke and methodology. It followed the recommendations of the EAN and ERS statement/consensus review documents (for details of the process refer to the Supporting information) [37–39].

The task force developed a document focusing on the following main topics:

1) Sleep–wake disorders, such as sleep-related breathing disorders, insomnia and RLS/PLMS disorder, as risk factors of stroke
2) Effect of treatment of SWDs on prevention of stroke
3) Frequency of SWDs as a consequence of stroke
4) Outcome of sleep-related breathing disorders and possible treatment effects of SWDs in patients with acute stroke

The task force did not consider studies in subarachnoid haemorrhage and excluded studies on less common sleep–wake and circadian rhythm disorders and studies assessing their association with stroke for practical reasons.

These topics were organized into 13 research questions according to the PICO format (Table 1 and Supporting information).

A systematic literature search was performed between March and July 2017. A final update search was performed in January 2019. Searches for each research question were performed applying a stepwise hierarchical approach. At first, possible systematic reviews and meta-analyses were searched starting from 1990. Then, (i) in the case of retrieval of systematic reviews or meta-analyses, primary studies with proper design were searched setting the time limit at the end of the systematic review search update; (ii) in the case of absence of systematic reviews or meta-analyses, primary studies were searched starting from 1990.

**Table 1 Research questions**

<table>
<thead>
<tr>
<th>Pre-stroke phase</th>
<th>Post-stroke phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1. Causation</td>
<td>Is SDB an independent risk factor of stroke?</td>
</tr>
<tr>
<td>1.2. Therapy</td>
<td>Does treatment of SDB prevent stroke?</td>
</tr>
<tr>
<td>2.1. Causation</td>
<td>Is insomnia an independent risk factor of stroke?</td>
</tr>
<tr>
<td>2.2. Therapy</td>
<td>Does treatment of insomnia prevent stroke?</td>
</tr>
<tr>
<td>2.3. Causation</td>
<td>Is RLS/PLMS an independent risk factor of stroke?</td>
</tr>
<tr>
<td>2.4. Therapy</td>
<td>Does treatment of RLS/PLMS prevent stroke?</td>
</tr>
<tr>
<td>3.1. Prevalence</td>
<td>What is the frequency of SDB in stroke patients?</td>
</tr>
<tr>
<td>3.2. Prognosis</td>
<td>Does SDB affect mortality and outcome after stroke?</td>
</tr>
<tr>
<td>3.3. Therapy</td>
<td>Does treatment of SDB have any impact on mortality and outcome after stroke?</td>
</tr>
<tr>
<td>4.1. Prevalence</td>
<td>Is the frequency of insomnia increased in stroke patients?</td>
</tr>
<tr>
<td>4.2. Therapy</td>
<td>Does treatment of insomnia have any impact on mortality and outcome after stroke?</td>
</tr>
<tr>
<td>4.3. Prevalence</td>
<td>Is the frequency of RLS/PLMS increased in stroke patients?</td>
</tr>
<tr>
<td>4.4. Therapy</td>
<td>Does treatment of RLS/PLMS have any impact on mortality and outcome after stroke?</td>
</tr>
</tbody>
</table>

Published studies were identified from the National Library of Medicine’s MEDLINE database and Elsevier’s Embase database. Specific search strategies used a combination of exploded terms and free text, using concepts regarding sleep disorders, stroke and treatment for sleep disorders when needed (refer to the Supporting information for the detailed search strategies). All abstracts or full papers were reviewed independently by two task force members with expertise in methodology, to identify potentially relevant studies and to assess studies for inclusion. The studies included were assessed by clinical experts in the relevant topics. The inclusion criteria for eligible studies are reported in detail in the Supporting information.

The quality of evidence of each study was classified according to topic domain and type of publication (systematic review or primary study). Systematic reviews were assessed using the criteria from the AMSTAR checklist [40]. According to the topic, primary studies were assessed with the Classification of Evidence Schemes of the Clinical Practice Guideline Process Manual of the American Academy of Neurology [41]. Briefly, each study is graded according to its risk of bias from class I (highest quality) to class IV (lowest quality).

Statements for each research question were developed by each group of experts, with final consensus by the whole task force. The statements aim to provide an overview of the literature and current practice. They do not make recommendations for clinical practice. The questions of the scenarios having no or little...
evidence were considered to identify research gaps and direct future research projects.

A total of 12,870 studies was evaluated for possible inclusion; full texts of 445 studies were assessed and 88 studies met the inclusion criteria (Figs S1–S38). A descriptive summary of the included studies with details about study design, number and characteristics of enrolled patients, intervention(s) and comparator(s), outcomes and results are provided in the tables in Supporting information.

Results

The main results are presented in Table 2.

Sleep-disordered breathing and risk of stroke

Is SDB an independent risk factor for stroke?

The possible role of OSA as a risk factor for stroke has been highlighted since the first studies using snoring as a surrogate marker of OSA [42]. According to a recent meta-analysis, habitual snoring, defined as occurring at least three nights per week, carries a 25% additional risk for stroke compared to non-snorers [43]. However, snoring is a symptom that can occur in the absence of respiratory events during sleep, and thus objective measurement of SDB is an essential part of stroke risk evaluation.

Results of literature search.

• Nine systematic reviews were included [44–52]. The original studies included in the systemic reviews were of class I and II quality.
• Fourteen primary studies of class I and II quality were included. Five studies explored the association of SDB and incident stroke in the general population [53–56]. Five studies evaluated prospectively [57–59] or retrospectively [60,61] the incidence of stroke or cardiovascular events in patients studied for suspected OSA. Three studies compared cardiovascular outcomes in patients with atrial fibrillation according to presence/absence of OSA [62–64]. A retrospective study assessed incident stroke in patients with previously diagnosed with OSA and end-stage renal disease [65]. A retrospective study analysed the incidence of stroke in community-dwelling men who underwent comprehensive sleep studies [66].

Overview of the evidence. The results of six systematic reviews with meta-analyses show that OSA approximately doubles the risk for stroke [relative risk (RR) ranging from 2.02 to 2.24] in untreated OSA patients over a follow-up period of 3–10 years (Table S1) [44–46,48,52,60]. These results stem from primary studies, the majority of which adjusted for confounding factors (age, sex, body mass index, smoking, alcohol consumption, hypertension and diabetes). The results were also confirmed in the elderly subgroup [50]. However, in patients with percutaneous coronary intervention no significant trend was found (Table S2) [49,51].

The incidence of stroke in OSA patients has been evaluated based on the analysis of large databases. Two studies reported an increased risk, especially in young to middle-aged OSA patients [53,54]. In community-dwelling elderly men, the severity of nocturnal hypoxaemia rather than AHI appeared to carry a significant risk, especially in patients who experienced a fatal stroke during follow-up [66]. A relatively small

Table 2  Sleep disorders as independent risk factors and modulators of stroke outcome

<table>
<thead>
<tr>
<th>Evidence Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sleep disorders as risk factors for stroke</strong></td>
</tr>
<tr>
<td>Sleep-disordered breathing</td>
</tr>
<tr>
<td>Treatment of sleep-disordered breathing</td>
</tr>
<tr>
<td>Insomnia</td>
</tr>
<tr>
<td>Treatment of insomnia</td>
</tr>
<tr>
<td>RLS/PLMS</td>
</tr>
<tr>
<td>Treatment of RLS/PLMS</td>
</tr>
<tr>
<td><strong>Sleep disorders and stroke outcome</strong></td>
</tr>
<tr>
<td>Sleep-disordered breathing</td>
</tr>
<tr>
<td>Treatment of sleep-disordered breathing</td>
</tr>
<tr>
<td>Insomnia</td>
</tr>
<tr>
<td>Treatment of insomnia</td>
</tr>
<tr>
<td>RLS/PLMS</td>
</tr>
<tr>
<td>Treatment of RLS/PLMS</td>
</tr>
</tbody>
</table>

Results of a systematic review performed between March and July 2017 and a final update search performed in January 2019. ‘Studies’ refers to primary studies published after the SR/MA. BDZ/BDZR, benzodiazepines and benzodiazepine-related drugs; CPAP, continuous positive airway pressure; OSA, obstructive sleep apnoea; PLMS, periodic limb movements in sleep; RLS, restless limb syndrome; SR/MA, systematic reviews/meta-analyses.
population study confirmed an increased risk for incident stroke in patients with moderate–severe OSA [55].

The only prospective study reported a six-fold risk of experiencing stroke during follow-up in women with untreated OSA, especially in patients <65 years of age [53]. Two prospective studies in patients with coronary artery disease reported an increased risk for major adverse coronary or cerebrovascular event, but did not analyse stroke data specifically, probably due to the small sample size [58,59].

Retrospective studies in OSA patients yielded variable results. The study by Kendzerska et al. [60] reported that stroke in OSA was significantly associated with gender, age, hypertension and history of previous stroke, but not with OSA severity assessed by AHI. The only sleep variables associated with stroke were total sleep time and frequency of nocturnal awakenings. An increased risk for all-cause and cardiovascular mortality, including stroke, was found in OSA patients, but specific data on stroke were not reported [61].

Three studies examined the risk of stroke in patients with OSA and atrial fibrillation. Two studies reported a four-fold risk of stroke in OSA patients [62,63] and a positive relationship between such risk and OSA severity [63]. Conversely, in elderly subjects with atrial fibrillation, OSA was not associated with increased cardiovascular risk, although OSA patients showed an increased risk for hospitalization [64]. Finally, in a retrospective study of patients with end-stage renal disease followed for 1.6 years, OSA exerted a protective effect against mortality and ischaemic stroke or myocardial infarction (Table S3) [65].

**Statements.**

1) Untreated severe OSA doubles the risk for incident stroke.

2) Such risk appears especially relevant in young to middle-aged patients, without differences between men and women.

3) Evidence on OSA-associated risk for stroke in patients with coronary artery disease or atrial fibrillation is still insufficient, but available data suggest an increased risk in these populations, with the possible exception of elderly patients.

**Recommendation for future research.** Future research needs to focus on the identification of subgroups of OSA patients who may experience a high risk for incident stroke, especially regarding age, gender, comorbidities (e.g., renal failure, atrial fibrillation), severity of OSA based on AHI, or hypoxaemia. Development of biomarkers of increased risk would be clinically desirable, in order to implement stronger preventive actions. The mechanisms responsible for the increased risk and studies on the types of stroke occurring more frequently in OSA patients should be defined.

**Does treatment of SDB prevent stroke?**

Continuous positive airway pressure (CPAP) therapy is well recognized to abolish obstructive events during sleep and substantially improve their consequences, especially daytime sleepiness, neurocognitive deficits and driving performance. Whilst earlier observational studies demonstrated improved cardiovascular outcomes with CPAP therapy, more recent randomized controlled trials (RCTs) have shown no improvement [67,68]. Thus, the potential benefit of CPAP therapy in preventing stroke is unproven.

**Results of literature search.**

- Four systematic reviews were included [69–72]. The original studies included in the systematic reviews were of class I or II quality.
- Four primary studies of class III or IV quality were included. Two studies assessed CPAP [73,74]. Two studies assessed the effect of uvulopalatopharyngoplasty (UPPP) [75] or tracheostomy [76].

**Overview of the evidence.** Khan et al. [72] included seven RCTs, with SAVE having the highest weight in the meta-analysis [68]. CPAP treatment was compared with no active intervention in six RCTs; only one trial compared it with nocturnal supplemental oxygen [77]. Stroke incidence was not affected by CPAP treatment in the overall population or after the exclusion of low CPAP adherence trials and after the exclusion of the SAVE trial. Sensitivity analysis for CPAP treatment at an average of ≥4 h per night versus matched trial controls that never used CPAP revealed a significant risk reduction in stroke incidence (P = 0.01, $\hat{f} = 0\%$) [RR 0.56, 95% confidence interval (CI) 0.37–0.84]. Risk of bias was identified in RICCADSA (Table S4) [77–80].

Abuzaid et al. [69] included four RCTs with one of them not showing up in the forest plot despite assessing stroke outcome [79]. All these trials are part of a meta-analysis reported by Khan et al. [72]. CPAP treatment was not associated with a reduction in the incidence of stroke (P = 0.86, $\hat{f} = 0\%$) (RR 1.01, 95% CI 0.73–1.38) or transient ischaemic attack (TIA) (P = 0.24, $\hat{f} = 30\%$) (RR 1.36, 95% CI 0.69–2.68). All trials were deemed to have low risk of bias and high quality body of evidence for the outcomes. The work reported by Parra et al. [78,81] is included with the 2-year rather than the 5-year available outcomes (Table S4).

Kim et al. [71] included one RCT, five cohort and two administrative health data studies. They did not show any effect of CPAP treatment on stroke incidence. The RCT had limited power to assess the effect.
of CPAP on stroke separately and the administrative studies had critical issues of validity and bias. A meta-analysis of three of the cohort studies showed 73% overall stroke risk reduction with CPAP; non-significant heterogeneity \((P = 0.46, \, I^2 = 0\%\) \((RR 0.27, \, 95\% \text{ CI} 0.14–0.53)\) [82–84]. Poor adherence to CPAP was recorded in all but one study [82]. The high vascular recurrence rate in this population raises concerns on the general validity of the results (Table S4) [82].

Halle et al. [70] have reviewed the effect of the surgical treatment of OSA on cardiovascular outcomes. Only two studies, amongst the 33 included, reported stroke as an outcome; one was assessing UPPP and another was assessing tracheostomy (Table S4) [75,76].

Uvulopalatopharyngoplasty was associated with a significant decrease in the incidence of ischaemic \((0.30\% \text{ vs. } 1.76\%, \, P < 0.0001)\) and haemorrhagic \((0.07\% \text{ vs. } 0.47\%, \, P < 0.0001)\) stroke; relative risk reduction after adjustments for age, sex, low income, medical comorbidities and medication was 0.41 \((95\% \text{ CI } 0.27–0.62)\) and 0.53 \((95\% \text{ CI } 0.38–0.73)\), respectively [75]. Limitations of that study include the relatively small number of older patients, unknown OSA severity (insurance reimbursement claims) and absence of data on possible CPAP treatment in the non-UPPP treated population. Thus, the task force considered the quality of the study insufficient to allow any statement (Table S5).

Tracheostomy compared to the conservative management group of weight-loss recommendation was associated with reduced vascular morbidity \((P = 0.046, \, \text{chi-squared } 3.98)\) and a smaller increase in the overall prevalence of ischaemic infarcts \((9.8\% \text{ to } 11.0\% \text{ vs. from } 5\% \text{ to } 10.2\%)\) in the 7-year follow-up period; it is unclear whether the latter was statistically significant [76]. This was a retrospective analysis of prospectively followed up patients from 1972 to 1980 (Table S5).

Catalan-Serra et al. [73] examined the incidence of stroke in OSA patients with CPAP treatment in a prospective, observational cohort from Spain. In the 6-year median follow-up, OSA with AHI ≥ 30 events per hour and CPAP not prescribed or compliance <4 h per day had significantly higher cumulative incidence of stroke compared with the reference group of individuals with AHI < 15 events per hour [log-rank test \(11.87, \, P = 0.001; \, \text{hazard ratio (HR) } 3.42, \, 95\% \text{ CI } 1.37–8.52)\) after adjustments for age, body mass index, hypertension, sex, smoking habit, Epworth Sleepiness Scale and atrial fibrillation (Table S5).

Wu et al. [74] examined the effect of CPAP treatment in a retrospective cohort of OSA patients with coronary artery disease and recent percutaneous coronary intervention. In a 5-year mean follow-up period, there was no impact of CPAP treatment on stroke incidence with the trial recording a small number of cerebrovascular events (Table S5).

**Statements.**

1) Observational cohort studies suggest that CPAP treatment is associated with a reduced risk of stroke in patients with OSA, but results are very variable.

2) In meta-analyses of RCTs, CPAP treatment is not associated with stroke risk reduction in OSA patients; however, patients adherent to CPAP therapy (>4 h per day) may benefit.

3) There is insufficient evidence on other treatment options than CPAP.

**Recommendations for future research.** Further RCTs are needed to assess the effect of CPAP treatment with good compliance (>4 h per day) on stroke risk reduction, especially in subgroups with sleepiness, high risk profile and with severe OSA. Other OSA treatment modalities, such as mandibular advancement devices, also need to be addressed in RCTs.

**Insomnia, RLS/PLMS and risk of stroke**

**Is insomnia an independent risk factor for stroke?**

Only in recent years, insomnia has been found to be associated with cardiovascular and metabolic comorbidities, especially when linked with objective short sleep duration [85,86]. Uncertainties remain regarding the potential risk association for stroke, because of limitations including the variability in diagnostic criteria for insomnia and the confounding influence of comorbidities.

**Results of literature search.**

- Two systematic reviews were found. One systematic review included 15 prospective studies (cohort, sub-cohort and population-based studies) [87,88]. The original studies included in the systematic review by He et al. [87] were of class I quality.
- Two case-control studies (nested in an administrative cohort) of class III quality were included [89,90].

**Overview of the evidence.** The systematic review by He et al. [87] showed that insomnia increases the risk of future cardiovascular or cerebrovascular events with an odds ratio below 1.3, similar to most studies linking long and short sleep with stroke [26,32]. However, when considering only studies with stroke as outcome, data were insufficient to support a link between insomnia and stroke. In fact, only two studies in this meta-analysis assessed the relationship between insomnia and stroke [91,92]. In the study by Helbig et al.
there were 917 strokes observed in a cohort of 17,604 subjects followed for a mean period of 14 years. After adjusting for other risk factors, symptoms of insomnia and short sleep duration were not predictive of stroke in either sex. In the study by Westerlund et al. [92], including 41,192 adults with a follow-up of 13.2 years, 1,685 strokes were observed. The authors found that insomnia was unrelated to risk of overall cardiovascular events. However, short sleepers (≤5 h) with frequent insomnia symptoms had an increased risk (HR 1.26–1.39) (Table S6).

The systematic review by Kwok et al. [88] did not find an association between poor sleep quality and stroke outcome (Table S6).

The second study retrospectively compared the risk of stroke in patients with (n = 38,663) or without (n = 38,671) BDZ therapy. Compared to non-treated patients, those with a lower annual dosage of BDZs (<1 g) or duration (<30 days) had a significantly lower risk of stroke in the elderly group, whilst patients with a higher annual dosage (≥4 g) or duration (≥95 days) of BDZ use had a higher risk of stroke in all age groups [97].

Taipale et al. [99] investigated the risk of ischaemic, haemorrhagic or any stroke associated with incident BDZR use in 45,050 community-dwelling individuals with Alzheimer’s disease. Compared with non-use, BDZR use was associated with an increased risk of any stroke (adjusted HR 1.21, 95% CI 1.04–1.40) and ischaemic stroke (adjusted HR 1.21, 95% CI 1.02–1.44), but the association between BDZR use and haemorrhagic stroke did not reach statistical significance (adjusted HR 1.26, 95% CI 0.91–1.74). The use of BDZRs was associated with a similar risk to BDZ use. The use of BDZs/BDZRs is linked with an increased risk of cognitive dysfunction, dementia and mortality and possibly also stroke, especially in high dosage and long-term use. This effect may be related also to an indication bias: patients who are in a worse general or neurological condition suffer more frequently from insomnia and may receive BDZ/BDZRs more frequently. Recommendations for future research. There is a need for more prospective studies, using standardized and validated self-assessment questionnaires, and objective measures for evaluating insomnia severity. Repeated measures of sleep issues are required, as insomnia symptoms may change over time. Information about the presence of comorbidity with other sleep disorders, and data regarding treatment of insomnia during the follow-up period, should be included.

Does treatment of insomnia prevent stroke?
Chronic use of benzodiazepines and related drugs (BDZRs) (such as zopiclone and zolpidem) has been linked in several studies with increased risk of impaired cognitive function, dementia and mortality [93–96]. However, the effect of insomnia treatment on stroke risk has rarely been assessed.

Results of literature search.
• No systematic reviews were identified.
• Three primary studies (two of class II quality, one of class III) were included in our review of the evidence [97–99].

Overview of the evidence. Zhu et al. [98] observed a significant decrease in ischaemic stroke risk in users of gamma-aminobutyric acid (GABA) agonists. In contrast, the use of benzodiazepines (BDZs) failed to improve the risk of ischaemic stroke. A significant decrease in ischaemic stroke risk was observed amongst patients using non-BDZs [adjusted odds ratio (OR) 0.48, 95% CI 0.32–0.72]. BDZ use was not associated with ischaemic stroke (adjusted OR 1.25, 95% CI 0.91–1.72). Adjusted ORs in patients using non-BDZs were 0.75 (95% CI 0.39–1.46) for 0–5 years, 0.44 (95% CI 0.25–0.77) for 5–10 years and 0.38 (95% CI 0.16–0.90) for >10 years. The risk of ischaemic stroke decreased progressively with duration of non-BDZ use (P < 0.001) [98].

Is RLS/PLMS an independent risk factor of stroke?
Restless limb syndrome with short total sleep time and PLMS with sleep fragmentation may cause a sympathetic hyperactivity, activate the hypothalamic pituitary adrenal axis, and increase the levels of pro-inflammatory cytokines and circulating catecholamines [23,100], which may favour hypertension and stroke.
Results of literature search.

- Two systematic reviews on RLS including 18 studies and eight studies, respectively, were considered [101,102]. For PLMS there is a recent systematic review that included five studies [103]. The original studies included in the systematic reviews were of class II and III quality.
- Two additional primary studies of class II [104] and class IV quality [105] were identified.

Overview of the evidence.

The first systematic review on RLS concluded that available evidence on RLS as a prognostic factor for incident cardiovascular events and all-cause mortality was limited and inconclusive; two of six cohort studies of moderate quality found an association between RLS and stroke [101]. However, none of the primary studies included in this review met class I criteria and the remaining studies were of limited quality. A major problem of these studies is the diagnosis and classification of RLS (Table S8).

The most recent systematic review with meta-analysis on RLS did not provide any evidence for an increased stroke risk in RLS [102]. In the unadjusted analyses of prospective observational studies, RLS patients were found to have significantly higher risk for cerebrovascular ischaemia ($P = 0.01$) and all-cause mortality ($P = 0.04$) compared to controls. However, in the analysis adjusted for potential confounders, RLS patients were found to have a higher risk only for all-cause mortality (adjusted HR 1.52, $P = 0.002$) (Table S9).

The meta-analysis on PLMS included 9823 patients with PLMS and 9416 controls from five studies [103]. The authors performed meta-regression and subgroup meta-analysis to detect the potential confounding factors. An increased prevalence of stroke in patients with PLMS compared to controls (OR 1.267, within 8 years of a diagnosis of PLMS) was found (Table S9).

In the first additional primary study, Winkelman et al. [104] published data about the MrOS Sleep Study that included 2823 community-dwelling men 65 years or older. RLS was identified by self-report of a physician diagnosis of RLS. A periodic limb movement of sleep index (PLMI) was derived from unattended in-home polysomnography (PSG). Incident cardiovascular events were centrally adjudicated during $8.7 \pm 2.6$ years of follow-up. RLS and PLMI were not associated with stroke (Table S10).

The second additional primary study was a case-control study ($n = 487$ primary RLS patients and 354 controls) that reported no significant association between RLS and stroke [105].

Statements.

1) Current evidence does not suggest an increased risk of stroke in patients with RLS.
2) Periodic limb movements in sleep may represent an independent risk factor for stroke.

Recommendations for future research. Long-term controlled cohort studies using strict internationally accepted definitions and controlling of comorbidities and other confounders to the presence of RLS are needed. The concomitant evaluation of PLMS in RLS patients may be needed but represents at the same time a major logistical challenge.

Does treatment of RLS/PLMS prevent stroke?

Considering the possible link between PLMS and stroke, treatment of RLS patients (presenting PLMS in 70%–80% of cases) could be beneficial in reducing stroke risk.

Results of literature search

- No systematic reviews were found.
- No primary studies were found.

Overview of the evidence

No data to be discussed.

Statements

Based on the lack of evidence, no statement can be made.

Recommendations for future research

Long-term studies on the effect of RLS/PLMS treatment on stroke are required. Drugs with different impact on sleep fragmentation or PLMS should be compared.

Frequency of SDB after stroke and its impact on outcome

What is the frequency of SDB in stroke patients?

Early studies [106,107] suggested a high frequency of SDB after stroke, which has been confirmed in many subsequent more recent studies. Since SDB is frequent in the general population and stroke can lead to de novo SDB, it remains uncertain for individual patients whether SDB is pre-existing or a consequence of stroke [31]. The form of SDB (central sleep apnoea or OSA) and its evolution after stroke have only rarely been assessed. In addition, the differentiation between obstructive and central events was unclear/questionable in most studies.

Results of the literature search.

- Three systematic reviews/meta-analyses on the frequency of SDB in stroke were retrieved [8,108,109].
The original studies included in the systematic reviews were of quality ranging from class I to class III.

- Six additional primary studies of class II or III quality were identified [110–115].

**Overview of the evidence.** The systematic review by Johnson and Johnson [108] included 29 studies involving 2343 patients with TIA, ischaemic or haemorrhagic stroke. The frequency of SDB with AHI >10 was 63% (95% CI 58.8–68%) and with AHI >30 was 29% (95% CI 21.1–37%). Only 7% of the SDB was primarily central apnoea. There was no significant difference in SDB prevalence by event type, timing after stroke or type of monitoring. Males had a higher percentage of AHI >10 than females (65% compared to 48%; \( P = 0.001 \)). Patients with recurrent strokes had a higher percentage of AHI >10 than initial strokes (7% compared to 5%; \( P = 0.013 \)). Patients with cardioembolic aetiology had a lower percentage of SDB than other aetiologies (Table S11).

The systematic review by Dong et al. [8] included a total of 37 studies. Eighteen studies assessed patients within 7 days, 10 after 7–28 days and three studies over 28 days after stroke. The frequencies for the different AHI cut-offs were found: AHI >5 in 70.4% (95% CI 62.1–78.7%), AHI >20 in 39.5% (95% CI 31.6–47.4%), and AHI >30 in 30.1% (95% CI 23.1–37.0%) (Table S11).

The meta-analysis by Seiler et al. [109] included a total of 89 studies where at least 10 patients were assessed, and full PSG or a portable device was used for diagnosis (Table S11). Fifty-four studies assessed patients <1 month after stroke, 23 studies 1–3 months after stroke and 12 studies >3 months after stroke. The distribution of stroke types was as follows: ischaemic stroke 5275, haemorrhagic stroke 302, TIA 405, undefined 1188. The frequencies for the different AHI cut-offs were found: AHI >5 in 70%–90% (95% CI 66.6%–74.8%), AHI >20 in 40% (95% CI 33.45%–46.85%), AHI >30 in 30% (95% CI 24.4%–35.5%). The mean AHI was 26 (95% CI 21.7–31.2, \( n = 44, F^2 = 24% \)), the mean obstructive apnoea index was 12 (95% CI 6.5–21.1, \( n = 12, F^2 = 32\% \)), the mean central apnoea index was 5 (95% CI 2.8–10.0, \( n = 13, F^2 = 12\% \)), and all the other events were hypopnoeas, adding up to the overall mean AHI. The frequency of SDB did not differ depending on the interval between stroke and the sleep study; however, three studies providing longitudinal observations of SDB evolution suggested improvement over time. There was no difference whether SDB was diagnosed with PSG or a portable device. Few studies assessed risk factors/predictors of SDB in stroke patients. Six new studies, published after the most up-to-date systematic review, did not add new data on this topic (Table S12) [95,110–115]. Most studies published did not find any relationship between topography of stroke and frequency/severity of SDB, although a few reports suggested an association between central SDB and supratentorial stroke and obstructive SDB and infratentorial stroke [31].

**Statements.**

1. The prevalence of SDB is high in stroke patients; about 30% of stroke patients present with severe SDB (AHI > 30).
2. Portable cardiorespiratory polygraphy is sufficient to assess the presence/severity of SDB in stroke patients in clinical practice.
3. Predictors of SDB in stroke patients have not been adequately assessed.
4. The link between stroke characteristics (type, severity, topography, aetiology) and severity or type of SDB is insufficiently understood.
5. The evolution of SDB over time remains uncertain.

**Recommendations for future research.** New tools are needed for the assessment of severity, type and implications of SDB post-stroke. Predictors of SDB in stroke patients should be determined. More longitudinal studies are needed to assess the evolution of severity and optimum time for treatment interventions. The impact of stroke type, severity and topography could be of clinical/pathophysiological interest but is not well known. The significance of different subtypes of central sleep apnoea is poorly known.

**Does SDB affect mortality and outcome after stroke?** Untreated severe OSA is associated with a risk of incident stroke. The risk is especially increased in young to middle-aged patients and possibly associated with other cardiovascular comorbidities in OSA patients. As the incidence of severe OSA is high in stroke patients, the question arises whether SDB might influence survival and outcome in stroke patients.

**Results of the literature search.**

- The literature search revealed two systematic reviews [116,117]. The original studies included in the systematic reviews were of quality ranging from class I to class IV.
- Five primary studies of class III quality [111,113,114,118,119] were included.

**Overview of the evidence.** One systematic review included seven cohort studies and one cross-sectional study with 47–174 patients [116]. The systematic review with meta-analysis of 13 hospital-based cohort studies focused on stroke (five studies, 860 patients) and mortality (11 studies, 930 patients) [117]. The mean ages in both reviews were between 56 and 79 years; 41%–
87% of subjects were males. The reviews were limited by different levels of severity, heterogeneous adjustments for confounders and a variety of follow-up periods. The advantages of the systematic review with meta-analysis were the prospective character of the cohort studies, the large sample size and the missing evidence of significance between study heterogeneity and of change in sensitivity analyses for the outcomes. The reviews showed consistently that SDB increases the risk of recurrent stroke and all-cause mortality. However, the effects of SDB on the neurological outcome, e.g. measured as a modified Rankin Scale score, were not reported (Table S13).

New studies, published after the most up-to-date systematic review, did not find an independent association between SDB and mortality [111,114,119]; however, three of them [113,114,118] found an association of SDB with a worse neurological outcome (e.g. modified Rankin Scale score, Bartel Index, early neurological deterioration) (Table S14).

**Statements.**

1) Obstructive sleep apnoea syndrome is a risk factor for recurrence of stroke or TIA.

2) Obstructive sleep apnoea syndrome in stroke patients may be associated with an increase in all-cause mortality [27] and worsen the neurological outcome.

**Recommendations for future research.** Future studies should include larger sample sizes, adjust appropriately for potential confounders, and evaluate neurological outcomes in greater detail, including cognitive functions. Large, long-term prospective studies are required in patients with SDB but without previous cerebrovascular events.

**Does treatment of SDB have any impact on mortality and outcome after stroke?**

Whilst SDB and, in particular, OSA is common in stroke patients and associated with an increased risk of recurrent stroke and all-cause mortality, the impact of treating SDB on neurological recovery and cardiovascular morbidity and mortality has only recently been explored.

**Results of the literature search.**

- The search revealed two updated systematic reviews with meta-analyses using CPAP or non-invasive ventilation (NIV) as treatment for SDB [120,121].
- A further two class II quality studies on the impact of CPAP on measures of vascular risk were published after the systematic search finished and were included [122,123].
- Seven primary studies of class II to IV quality using other interventions were included: one RCT using positional therapy [124] and six proof-of-concept studies or retrospective analyses using adaptive servo-ventilation, expiratory positive airway pressure, oxygen, transnasal insufflation, oropharyngeal muscle exercise or mirtazapine [125–130].

**Overview of the evidence.** The systematic review of Tsivgoulis et al. [120] focused on the acute stroke setting and included four RCTs using CPAP and one prospectively matched observational cohort study with NIV. The mean decrease in the National Institutes of Health Stroke Scale (NIHSS) score during the initial (≤30) days after acute ischaemic stroke was greater in NIV treated patients in comparison to controls (standardized mean difference 0.38, 95% CI 0.11–0.66; \( P = 0.007 \)). There was a risk for detection and performance bias and the authors concluded that NIV seems to be associated with greater short-term neurological improvement in acute ischaemic stroke patients with OSA, but acknowledged the limitations of the included primary studies (Table S15).

The second meta-analysis by Brill et al. [121] included 10 RCTs using CPAP (\( n = 564 \)) to improve stroke outcomes in acute and chronic stroke survivors with OSA (Table S15). The combined analysis of the stroke scales (NIHSS and Canadian Neurological Scale) showed an overall improvement with CPAP (standardized mean difference 0.5406, 95% CI 0.0263–1.0548) but was limited by a considerable heterogeneity across the studies. The results of the neurocognitive tests, depression scores and sleepiness were inconsistent across the trials. The adherence to CPAP was acceptable once the treatment was tolerated (mean CPAP usage across the trials 4.53 h per night, 95% CI 3.97–5.08 h per night). All trials struggled with recruitment and overall acceptance of CPAP which partially limits the power of the trials and the effectiveness of the intervention. The OR of dropping out with CPAP was 1.83 (95% CI 1.05–3.21; \( P = 0.033 \)).

Recurrent cardiovascular events and mortality have been assessed in only one RCT (\( n = 140 \)) and revealed a longer time to the next cardiovascular event (14.9 vs. 7.9 months), but no difference in the overall cardiovascular event-free survival or all-cause mortality over 2 years [81]. However, at 5-year follow-up, CPAP was associated with a higher cardiovascular survival rate compared to the control group [78]. A non-randomized observational study (\( n = 166 \)) showed that an AHI >20 and intolerance of CPAP has an HR of 2.87 (95% CI 1.11–7.71) for a non-fatal cardiovascular event [82]. Bravata et al. [122] reported no difference in neurological status and functioning when comparing CPAP therapy with no CPAP in an intention-to-treat analysis. However, CPAP-compliant patients demonstrated improved stroke outcome as
assessed by the NIHSS and modified Rankin Scale scores. Gupta et al. [123] reported no difference of vascular event incidence (primary outcome) at 12-month follow-up (3.33% in the CPAP group, 15% in the non-CPAP group, \( P = 0.23 \)). A modified Rankin Scale score improvement by \( ≥1 \) (secondary outcome) was found in significantly more patients in the CPAP group than in the non-CPAP group (53% vs. 27%, \( P = 0.03 \)) (Table S16).

There is very little or no evidence on the effect of specific SDB treatment alternatives, such as oropharyngeal muscle exercise [130], positional therapy [124] or mandibular advancement devices, or other positive airway pressure modes [127–129], oxygen [125] or pharmacotherapy [126], on stroke outcomes, cardiovascular events or mortality (Table S17).

**Statements.**
1) Current evidence suggests that CPAP is feasible in stroke survivors with OSA and may improve neurological recovery, sleepiness and depressive symptoms. It further suggests that treatment of post-stroke OSA with CPAP should be included in an integrated management of multiple risk factors such as anticoagulation for atrial fibrillation, control of hypertension and dyslipidaemia, exercise and weight reduction.

2) Acceptance of CPAP in the acute stroke setting within trials was mostly limited but, once accepted, compliance can be satisfactory.

3) There is insufficient evidence to permit statements on the use of other treatment modalities to influence stroke outcome.

**Recommendations for future research.** Future research needs to focus on stroke-specific multidisciplinary educational programmes for patients, staff and caregivers to enable stroke survivors to be more adherent to CPAP (mask-fitting, handling of the machine). Other research areas include the identification of patients who might have the highest likelihood of benefiting from the treatment, the optimal timing of treatment initiation and the use of meaningful and comparable neurocognitive and neurofunctional end-points in sufficiently powered trials.

**Frequency of insomnia and RLS/PLMS after stroke and their impact on outcome**

*Is the frequency of insomnia increased in stroke patients?*
Insomnia is highly prevalent in the general population and stroke can lead *de novo* to insomnia [27]. Accordingly, a recent meta-analysis of sleep electroencephalogram studies showed that stroke patients have a poorer sleep than controls, in terms of sleep efficiency, total sleep time and wake after sleep onset [131]. In addition, the presence of insomnia in stroke patients has been shown to be linked with cognitive impairment, anxiety and depression (and suicidality) and to have a bad impact on functional recovery and return to work [30,132–134]. Unfortunately, few studies addressed systematically the frequency of insomnia in stroke patients.

**Results of literature search.**
- No systematic reviews were found.
- Eight primary studies of class II and III quality were included [132,134–140].

**Overview of the evidence.** In a study of 277 consecutive patients assessed in the first month after onset 56.7% had complaints of insomnia and 37.5% had insomnia according to the *Diagnostic and Statistical Manual of Mental Disorders* (DSM) IV criteria [135]. In 18% of patients, insomnia appeared for the first time (*de novo*) after brain damage (Table S18).

In a study of 100 stroke patients, complaints of insomnia (as assessed by the insomnia-related items of the Hamilton depression scale) occurred in 68% of patients on admission and in 49% at 18 months after stroke. From 2 months, symptoms of insomnia were associated independently with depression. Living alone before stroke and age were other independent predictors of insomnia (Table S18) [136].

In a study of 40 stroke patients and 30 healthy controls assessed by the Sleep Habits Questionnaire, insomnia complaint was the most prevalent (37.5% vs. 6.7%; \( P = 0.007 \)). Female sex (OR 11.098, 95% CI 1.167–105.559; \( P = 0.036 \)) and fragmented sleep (OR 32.040, 95% CI 3.236–317.261; \( P = 0.003 \)) were risk factors for insomnia (Table S18) [137].

In a study of 366 patients assessed 3 months after stroke, insomnia (as assessed by a seven-item questionnaire) was found in 44% of them; an association with female gender, depression and lower stroke-related quality of life was observed [132]. In a study of 215 first-time stroke patients, insomnia (defined as the presence of at least one of the four following complaints: difficulty initiating sleep, difficulty maintaining sleep, early morning awakening and non-restorative sleep) 1 month after onset was found in 59.5%. Insomnia was found to be significantly associated with poorer physical functioning, general health and vitality scores [138]. In a study of 280 patients assessed 1 month after stroke, insomnia (as defined by DSM IV criteria) was found in 26.9% of patients and was associated with poorer functional recovery [139]. In a study of 441 patients assessed by self-report and interview at 1, 6 and 12 months after stroke, the point prevalence of insomnia (as assessed by three items of the Karolinska sleep questionnaire) at each time point...
in the year after stroke was stable at 30%–37% and more common in females. Fifty-eight (16%) of all participants reported ‘chronic’ insomnia, with symptoms at both baseline and 6 months later. At 12 months, this group was more likely to be depressed (OR 6.75, 95% CI 2.78–16.4), anxious (OR 3.31, 95% CI 1.54–7.09), disabled (OR 3.60, 95% CI 2.07–6.25) and not have returned to work, compared to those without insomnia over the same period (Table S18) [134].

In a study of 1062 first-time stroke patients, insomnia (as defined by DSM IV criteria) was reported by 38.4%. During the 6 years of follow-up, after adjusting for all confounders, insomnia was found to be associated with increased mortality (HR 1.66, 95% CI 1.10–2.48) (Table S18) [140].

Insomnia, as assessed by a variety of questionnaires and diagnostic criteria, is found in about one-third of stroke patients (range 27%–60%) and is associated with female gender, depression and poorer functional outcome. Data on long-term evolution are limited but suggest that post-stroke insomnia can persist over 12–18 months (Table S18).

**Statements.**

1) The prevalence of insomnia in stroke patients is increased (at least 30%).

2) There is a link between post-stroke insomnia, female gender and depression.

3) The evolution of insomnia over time is uncertain.

**Recommendation for future research.** There is a need of prospective studies on post-stroke insomnia using standard diagnostic tools and control groups. Risk factors for post-stroke insomnia (including stroke characteristics), evolution of insomnia over time and the prognostic role of insomnia on stroke-related outcomes should also be considered.

**Does treatment of insomnia have any impact on mortality and outcome after stroke?**

Insomnia is found in at least one-third of stroke patients and has a negative impact on functional evolution and quality of life (see above). Experimental and (few) human data suggest that GABA agonists (and also GABA antagonists) may have favourable effects on stroke evolution and outcome [141–143]. However, GABA agonists and BDZRs can lead in stroke patients to the re-emergence of neurological deficits [144,145]. In addition, treatment of insomnia with BDZRs increases the risk of dementia, mortality and possibly also stroke (see above). Finally, a recent meta-analysis suggested that the use of GABA receptor agonists (such as chlormethiazole or diazepam) may be detrimental in the acute phase of stroke [146]. Following single case reports only few studies on the treatment of insomnia in stroke victims were published.

**Results of literature search.**

- No systematic reviews were identified.
- One primary class IV quality study was included [147].

**Overview of the evidence.** In a study of 15 patients with subacute stroke and insomnia, hypnotics were found to improve sleep but not cognition, depression or functional outcome (Table S19) [147].

**Statement.** There are no systematic data on the effect of insomnia treatment on stroke outcome; worsening of neurological deficits with hypnotics has been reported.

**Recommendations for future research.** Randomized placebo-controlled trials should be conducted in patients with post-stroke insomnia. The presence of comorbidities such as depression should be taken into account. Because of higher mortality rates with most classes of psychotropic drugs, an RCT evaluating non-pharmacological approaches should also be considered.

**Is the frequency of RLS/PLMS increased in stroke patients?**

Restless limb syndrome/PLMS is highly prevalent in the general population and stroke can lead de novo to RLS and PLMS [27].

**Results of literature search.**

- A recent systematic review of three studies on PLMS was included [103]. The original studies included in the systematic review were of class II and III quality.
- Eight primary studies of class II and III quality were included [148–155]. Three studies evaluated prospectively the frequency of RLS/PLMS in stroke patients [149–151].

**Overview of the evidence.** The meta-analysis evaluated 158 PLMS patients with stroke and 88 PLMS patients without stroke from three studies [103]: a higher PLMI was found in stroke patients (Hedges’ g = 0.860, mean difference 4.43) (Table S20).

Gupta et al. [151] found a post-stroke prevalence of RLS of 10% in 346 consecutive patients. The most significant differentiating factor between patients with subcortical stroke and those with cortical stroke was pre-stroke RLS (23% vs. 3%, P < 0.001) (Table S21).

Shiina et al. [155] found a prevalence of RLS of 7.7% (3.3% post-stroke) out of 104 consecutive patients in a single hospital. In a prospective study of 137 patients, Lee et al. [149] found post-stroke RLS in 12.4% of patients (one patient with cortical and 16 patients with subcortical stroke). Schlesinger et al. [148] found pre-stroke RLS in 12.5% of patients (no post-stroke patients), statistically different from the 3% found in controls. In a prospective study, Medeiros et al. [150] found RLS in 12.5% of 97 stroke patients; all of them reported RLS before...
stroke. Patients with RLS had a significantly worse outcome at 3 and 12 months. In a prospective study, Boulos et al. [152] found RLS in 24% of 96 patients with TIA or stroke. The presence of RLS correlated with poorer outcome and depression. Another prospective study by Boulos et al. [153] found periodic limb movements in 50% of 30 patients with TIA or stroke. Two other recent studies suggested an association between post-stroke RLS and pontine stroke [156,157]. Manconi et al. [154] reported a similar frequency of PLMS in 169 stroke patients examined by conventional PSG in both the acute and subacute phase and no difference with 162 controls. Notably, stroke patients with PLMS were on a higher number of antihypertensive drugs (Table S21).

Gupta et al. [151] suggest that, out of 346 consecutive patients in a single stroke unit (80% males), 29 of 35 patients with pre-stroke RLS had imaging evidence for a subcortical stroke. The most significant difference between patients with subcortical stroke and those with cortical stroke was the presence of RLS before stroke (23% vs. 3%, \( P < 0.001 \)). However, 14 of the patients had an AHI >5 and no information on medication prior to stroke was available. In a prospective study of 137 patients, Lee et al. [149] found RLS in one patient with cortical stroke and 16 patients with subcortical stroke (Table S21).

**Statements.**
1) Data on the prevalence of RLS after stroke are inconclusive.
2) Restless limb syndrome in stroke patients is associated with subcortical/brainstem stroke and may be associated with a less favourable outcome.
3) Data on the prevalence and impact of PLMS after stroke are controversial, although PLMS in stroke patients may be more severe than in the general PLMS population.

**Recommendations for future research.** Larger prospective studies are needed to assess the frequency and impact of RLS and PLMS in stroke patients. Objective measures and assessment of confounding variables such as OSA should be considered.

**Does treatment of RLS/PLMS have any impact on mortality and outcome after stroke?**
Considering the impact of RLS/PLMS on cardiovascular functions and the possibility of an increased risk of stroke in patients with PLMS (see above) and of a poorer outcome in stroke patients with RLS, treatment of RLS/PLMS in this context could be of interest.

**Results of literature search.**
- No systematic reviews were identified.
- No primary studies were found.

**Overview of the evidence.** No data are available.

**Statement.** Based on the lack of evidence, no statement can be made.

**Recommendation for future research.** Prospective studies on the treatment of RLS and PLMS in stroke patients could be of interest.

**Concluding remarks**
This statement comes to three main conclusions. First, OSA (which affects 10%–20% of the general population and 50% of stroke patients) probably increases the risk of stroke and worsens its outcome. Secondly, CPAP possibly has a favourable effect on both stroke risk and outcome. Thirdly, non-apnoea SWDs (which are common in both the general population and stroke patients) may be associated with an increased stroke risk and a worse outcome. It is noteworthy that a recent meta-analysis published by Gottlieb et al. [35] suggested that long sleep duration hypersomnia and self-reported rapid eye movement sleep behaviour disorder, SWDs which were not analysed in our study, may also increase the risk of stroke.

Altogether, current evidence supports the hypothesis of a bidirectional link between SWDs and stroke and calls for a stronger collaboration between stroke and sleep clinicians [158].

Future research should test the hypothesis that different phenotypes of SDB and OSA (e.g. with sleepiness, insomnia or none of them) may be differently associated with various cardiovascular complications, including stroke. Overall, more studies are needed to determine the exact extent and pathophysiological base of the reported associations between SWDs and stroke and to identify the best options to improve stroke prevention and outcome through sleep-related interventions.

**Acknowledgements**
Carla Miltz is thanked for her assistance in the management of the manuscript and Romano Hönger for his assistance in the management of the task force; Elisa Baldin and Matthias Egger for assisting in the methodological process; Beatrice Minder and Doris Kopp for assisting in the search strategy design; Paul Twiddy and Jenny Emmel from the Library and Information Service, Leeds Teaching Hospitals NHS Trust, for the support in literature search; and Thorsten Steiner for additional input. This document was endorsed by the ERS Executive Committee on 17 October 2019, and by the EAN on 20 May 2019, the ESO on 4 June 2019 and ESRS on 22 May 2019. This article has Supporting information available from erj.ersjournals.com.
Disclosure of conflicts of interest
C.L.A. Bassetti has nothing to disclose related to this work. W. Randerath reports grants and personal fees for lectures from Weinmann, Philips Respironics, Resmed, Inspire, Heinen and Löwenstein and Genzyme, outside the submitted work. L. Vignatelli has nothing to disclose. L. Ferini-Strambi reports personal fees for advisory board work from UCB-Pharma, Italfarmaco, Resmed, Pfizer and Vitalaire Italia, outside the submitted work. A-K. Brill has nothing to disclose. M.R. Bonsignore has nothing to disclose. L. Grote reports grants and personal fees for lectures from Resmed and Itamar, personal fees for lectures from Philips, during the conduct of the study; personal fees for lectures from AstraZeneca, outside the submitted work; in addition, L. Grote has a patent for pharmacological treatment of sleep apnoea licensed to Desitin. P. Jennum has nothing to disclose. D. Leys reports compensation paid to hospital research funds and Adrinord for trials, advisory boards and symposia, from BMS/Pfizer, Boehringer Ingelheim and Bayer, outside the submitted work; and is vice editor of the European Stroke Journal. J. Minnerup has nothing to disclose. L. Nobili has nothing to disclose. T. Tonia acts as ERS methodologist. R. Morgan has nothing to disclose. J. Kerry has nothing to disclose. W.T. McNicholas has nothing to disclose. V. Papavasileiou has nothing to disclose.

Supporting Information
Additional Supporting Information may be found in the online version of this article:

Fig. S1. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S2. 3-5-17 run with Cohort Studies / Case Control Studies filters with temporal limit starting from the time limit of the most updated systematic review (2013 included).
Fig. S3. 18-1-19 run with temporal limit starting from 2017.
Fig. S4. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S5. 3-5-17 run with Cohort Studies / RCTs studies filters with temporal limit starting from the time limit of the most updated systematic review (2015 included).
Fig. S6. 18-1-19 run with temporal limit starting from 2017.

Fig. S7. 5-4-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S8. 3-5-17 run with Cohort Studies / Case Control studies filters with temporal limit starting from the time limit of the most updated systematic review (2016 included).
Fig. S9. 18-1-19 run with temporal limit starting from 2017.
Fig. S10. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S11. 3-5-17 run with RCTs and cohort studies filters with temporal limit starting from 1990.
Fig. S12. 18-1-19 run with temporal limit starting from 2017.
Fig. S13. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S14. 21-7-17 run with Cohort Studies / RCTs studies filters with temporal limit starting from 1990.
Fig. S15. 18-1-19 run with temporal limit starting from 2017.
Fig. S16. 14-3-17 with systematic reviews filter with temporal limit starting from 1990.
Fig. S17. 3-5-17 run with RCTs and cohort studies filters with temporal limit starting from 1990.
Fig. S18. 18-1-19 run with temporal limit starting from 2017.
Fig. S19. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S20. 18-1-19 run with temporal limit starting from 2017.
Fig. S21. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S22. 3-5-17 run with Cohort Studies / Case Control Studies filters with temporal limit starting from the time limit of the most updated systematic review (2015 included).
Fig. S23. 18-1-19 run with temporal limit starting from 2017.
Fig. S24. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.
Fig. S25. 13-7-17 run with Cohort Studies / RCTs studies filters with temporal limit starting from the time limit of the most updated systematic review (2015 included).
Fig. S26. 18-1-19 run with temporal limit starting from 2017.

Fig. S27. 5-4-17 run with systematic reviews filter with temporal limit starting from 1990.

Fig. S28. 3-5-17 run with Cohort Studies / Case Control Studies filters with temporal limit starting from 1990.

Fig. S29. 18-1-19 run with temporal limit starting from 2017.

Fig. S30. 5-4-17 run with systematic reviews filter with temporal limit starting from 1990.

Fig. S31. 3-5-17 run with RCTs and cohort studies filters with temporal limit starting from 1990.

Fig. S32. 18-1-19 run with temporal limit starting from 2017.

Fig. S33. 14-3-17 with systematic reviews filter with temporal limit starting from 1990.

Fig. S34. 21-7-17 run with Cohort Studies / RCTs studies filters with temporal limit starting from 1990.

Fig. S35. 18-1-19 run with temporal limit starting from 2017.

Fig. S36. 14-3-17 run with systematic reviews filter with temporal limit starting from 1990.

Fig. S37. 3-5-17 run with RCTs and cohort studies filters with temporal limit starting from 1990.

Fig. S38. 18-1-19 run with temporal limit starting from 2017.

Table S1. Systematic reviews including general population (6).

Table S2. Systematic reviews (3) including elderly patients (1), patients with percutaneous coronary intervention (2).

Table S3. Primary studies (14).

Table S4. Systematic Reviews (4).

Table S5. Primary studies (4).

Table S6. Systematic Reviews (2).

Table S7. Primary studies (2).

Table S8. Primary studies (3).

Table S9. Systematic Reviews (3).

Table S10. Primary Studies (2).

Table S11. Systematic reviews (3).

Table S12. Primary Studies (6).

Table S13. Systematic reviews (2).

Table S14. Primary Studies (5).

Table S15. Systematic reviews (2) on CPAP or non-invasive ventilation as treatment for SDB.

Table S16. Primary Studies (2) on CPAP or non-invasive ventilation as treatment for SDB.

Table S17. Primary Studies (7) using other interventions.

Table S18. Primary Studies (8).

Table S19. Primary Studies (1).

Table S20. Systematic Reviews (1).

Table S21. Primary Studies (8).

References


